Benitec announced this week that it has formed a collaboration with the Children's Cancer Institute Australia for Medical Research to develop an RNAi-based therapeutic for lung cancer.

The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi. A CCIA researcher and Benitec collaborator has previously demonstrated that beta III-tubulin inhibition using an expressed RNAi approach can sensitize tumors to various chemotherapeutics, it added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.